Critical Comparison: Pacific Biosciences of California (PACB) vs. Dextera Surgical (DXTR)
Pacific Biosciences of California (NASDAQ: PACB) and Dextera Surgical (NASDAQ:DXTR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitabiliy, earnings, analyst recommendations, valuation and risk.
Insider & Institutional Ownership
57.1% of Pacific Biosciences of California shares are owned by institutional investors. Comparatively, 9.6% of Dextera Surgical shares are owned by institutional investors. 17.8% of Pacific Biosciences of California shares are owned by insiders. Comparatively, 10.4% of Dextera Surgical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Valuation & Earnings
This table compares Pacific Biosciences of California and Dextera Surgical’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Pacific Biosciences of California||$96.50 million||3.33||-$70.10 million||($0.87)||-3.95|
|Dextera Surgical||$3.09 million||0.78||-$15.21 million||($1.83)||-0.15|
Dextera Surgical has higher revenue, but lower earnings than Pacific Biosciences of California. Pacific Biosciences of California is trading at a lower price-to-earnings ratio than Dextera Surgical, indicating that it is currently the more affordable of the two stocks.
This table compares Pacific Biosciences of California and Dextera Surgical’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Pacific Biosciences of California||-81.75%||-87.51%||-53.91%|
Risk and Volatility
Pacific Biosciences of California has a beta of 2.18, suggesting that its stock price is 118% more volatile than the S&P 500. Comparatively, Dextera Surgical has a beta of -1, suggesting that its stock price is 200% less volatile than the S&P 500.
This is a breakdown of current ratings and recommmendations for Pacific Biosciences of California and Dextera Surgical, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Pacific Biosciences of California||0||1||1||0||2.50|
Pacific Biosciences of California presently has a consensus price target of $10.00, suggesting a potential upside of 190.70%. Dextera Surgical has a consensus price target of $3.50, suggesting a potential upside of 1,196.30%. Given Dextera Surgical’s stronger consensus rating and higher probable upside, analysts clearly believe Dextera Surgical is more favorable than Pacific Biosciences of California.
Pacific Biosciences of California beats Dextera Surgical on 8 of the 12 factors compared between the two stocks.
Pacific Biosciences of California Company Profile
Pacific Biosciences of California, Inc. designs, develops and manufactures sequencing systems to help scientists resolve genetically complex problems. The Company is engaged in the development, manufacturing and marketing of an integrated platform for genetic analysis. Its Single Molecule, Real-Time (SMRT) technology enables single molecule, real-time detection of biological processes. It offers The SMRT Cell, Phospholinked nucleotides and The PacBio RS II and Sequel instruments. Its SMRT technology enables the observation of deoxyribonucleic acid (DNA) synthesis as it occurs in real-time by harnessing the natural process of DNA replication, which is actuated by the DNA polymerase. Its phospholinked nucleotides have a fluorescent dye attached to the phosphate chain of the nucleotide rather than to the base. The PacBio RS II and Sequel instruments include optics, automated liquid handling, a touchscreen control interface and computational hardware and software.
Dextera Surgical Company Profile
Dextera Surgical Inc., formerly Cardica, Inc., designs and manufactures stapling devices that enable the advancement of minimally invasive surgical procedures. The Company is engaged in commercializing and developing its MicroCutter 5/80 stapler based on its staple-on-a-strip technology for use by thoracic, pediatric, bariatric, colorectal and general surgeons. Its MicroCutter 5/80 is a commercially available cartridge-based microcutter device with approximately five millimeter shaft diameter, over 80 degrees of articulation, and an approximately 30 millimeter staple line cleared for specified indications for use in the United States, and in the European Union (EU) for a range of indications for use. It designs, manufactures and markets automated anastomotic systems used by surgeons to perform anastomoses during on- or off-pump coronary artery bypass graft procedures and these products include the C-Port xA system, the C-Port Flex A system and the PAS-Port Proximal Anastomosis System.
Receive News & Ratings for Pacific Biosciences of California Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacific Biosciences of California Inc. and related companies with MarketBeat.com's FREE daily email newsletter.